Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 159 participants.

Also called NCT02264288

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 159 participants (enrolled count) (from the registry)
Sponsor
Celularity Incorporated (from the registry)
Registry
  • NCT NCT02264288
Other papers using this trial's data
  • Human Placenta-Derived Cells (PDA-002) in Diabetic Foot Ulcer Patients With and Without Peripheral Artery Disease: A Phase 2 Multi-Center, Randomised, Double-Blind, Placebo-Controlled Trial International wound journal, 2025-10 DOI, PubMed 41077558, PMC12515546 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02264288. Randomized; triple masking; primary purpose treatment. Start 2014-10-23 (actual); primary completion 2018-02-27 (actual). Results posted on 2026-06-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.
Acronym
DFU-002
Condition
Peripheral Arterial Disease
Condition
Diabetic Foot
Intervention (Biological)
PDA-002
Intervention (Other)
Placebo
Lead sponsor
Celularity Incorporated (class: industry)

Record details

Record id
cardio:ct-nct02264288
Content hash
9abf369dae421608f366345289d201d15d642d54c6bee5d7350f5150cdb28f44